Document Type : Case Reports


1 Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Medical Mycology, Tarbiat Modares University, Tehran, Iran

3 Department of Microbiology, Shahr‑e‑Qods Branch, Islamic Azad University, Tehran, Iran

4 Department of Infectious and Tropical Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

5 Department of Parasitology and Mycology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

6 Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

7 Department of Pathology, Imam Hospital Complex, Tehran University of Medical Sciences, Iran

8 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran



There has been a rise in COVID-19-associated mucormycosis (CAM) cases, particularly in low-income countries. We describe a case of primary cutaneous mucormycosis after recovering from COVID-19 in a kidney transplant recipient who had a known case of diabetes mellitus. The patient developed cutaneous ulcers due to Rhizopus oryzae in the right hand. She did not recall any trauma or injury at the affected site. Based on the appearance of the wound we suspected that healthcare-associated mucormycosis could be the causative agent. Due to the initial misdiagnosis as a bacterial infection, the appropriate treatment was delayed, and the lesions progressed rapidly to necrotic ulcers with jagged margins that deteriorated during hospitalization. She underwent consecutive surgical interventions and received broad-spectrum antifungal therapy. Finally, the patient deceased after 32 days of hospital stay. We reviewed the previous case reports of cutaneous mucormycosis occurring in COVID-19 patients and described patient characteristics, predisposing factors, location of ulcers, clinical presentation, management, and outcome. This report and existing published literature indicate a poor outcome for cutaneous mucormycosis in COVID-19 patients and the importance of early diagnosis, aggressive multidisciplinary management, and regular follow-up as a life-saving measure, especially in immunocompromised patients.


Main Subjects

  1. Pragna KS, Harikanth KP, Pavithra J, Jakaraddi GN, Nagesh JD. Primary Cutaneous Mucormycosis in a Patient with Severe COVID-19 Infection. Journal of Clin Diag Res. 2021;15(12). [DOI:10.7860/JCDR/2021/51729.15757]
  2. Rashbi K S, Ali TF, PN D, CK S, Payyappilly RJ. COVID-19-Associated mucormycosis: Case series from a tertiary care hospital in South India. Access Microbiol. 2022 6;4(6):000360. [DOI:10.1099/acmi.0.000360] [PMID]
  3. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti A, Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021;186:289-98. [DOI:10.1007/s11046-021-00528-2] [PMID]
  4. Ambereen A, Rahman SA, Rehman S, Zaidi K, Arif SH. Mandibular mucormycosis following SARS-CoV-2 infection–A case report and review of literature. Clin Infect Dis. 2021;12:100099. [DOI:10.1016/j.clinpr.2021.100099] [PMID]
  5. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021;15(4):102146. [DOI:10.1016/j.dsx.2021.05.019] [PMID]
  6. Coerdt KM, Zolper EG, Starr AG, Fan KL, Attinger CE, Evans KK. Cutaneous mucormycosis of the lower extremity leading amputation in two diabetic patients. Arch Plast Surg. 2021;48(02):231-6. [DOI:10.5999/aps.2020.00549] [PMID]
  7. Belgaumkar VA, Chavan RB, Bhatt N, Ambike JS. Facial Ulcer: A Harbinger of Post-COVID-19 Mucormycosis, a Case Report. J Skin Stem Cell. 2021;8(1). [DOI:10.5812/jssc.117861]
  8. Menezes S, Kumar JS, Rudra OS, Nagral A. Cutaneous mucormycosis: an unusual cause of decompensation in a patient with ethanol-related cirrhosis with COVID-19 exposure. BMJ Cas Rep CP. 2022 Feb 1;15(2):e247399. [DOI:10.1136/bcr-2021-247399] [PMID]
  9. Tambe RR, Hinduja A, Sunil S, Varaiya A, Joshi AJIJoCCMP-r, Official Publication of Indian Society of Critical Care Medicine. Cutaneous Mucormycosis in a Patient of Severe COVID-19 Pneumonia: A Rarer than Rare Case Report. 2021;25(11):1318. [DOI:10.5005/jp-journals-10071-24026] [PMID]
  10. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient–case report and review of literature. J Med Mycol. 2021;31(2):101125. [DOI:10.1016/j.mycmed.2021.101125] [PMID]
  11. Hammoudi DA, Morar MM, Garbuzov A, Urias D, Katira KM. Lower extremity salvage in a diabetic patient with cutaneous mucormycosis and COVID-19 after open patella fracture. Och J. 2022;22(2):163-8. [DOI:10.31486/toj.21.0099] [PMID]
  12. Shah KM, West C, Simpson J, Rainwater YB. Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoid. JAAD Case Reports. 2021;15:80-1. [DOI:10.1016/j.jdcr.2021.06.012] [PMID]
  13. Annapoorani A, KasiViswanathan T. Post covid primary cutaneous mucormycosis in pediatric acute lymphoblastic leukemia induction-Case report. Pediatric Hematol Oncol J. 2021;6(4):S63. [DOI:10.1016/j.phoj.2022.03.163]
  14. Arana C, Cuevas Ramírez RE, Xipell M, Casals J, Moreno A, Herrera S, Bodro M, Cofan F, Diekmann F, Esforzado N. Mucormycosis associated with COVID‐19 in two kidney transplant patients. Transpl Infect Dis. 2021;23(4):e13652. [DOI:10.1111/tid.13652] [PMID]
  15. Zareshahrabadi Z, Emami A, Pakshir K, Roudgari A, Ghaffari B, Rezaei T, Shekarkhar G, Zomorodian K. COVID‐19‐associated facial cutaneous mucormycosis superinfection: A potentially life‐threatening disease. Clin Case Rep. 2022;10(7):e6103. [DOI:10.1002/ccr3.6103] [PMID]
  16. Arora A, Mohta A, Ghiya BC, Mehta RD. A Case Series of Mucocutaneous Mucormycosis and its Risk Factors among SARS-CoV-2 Patients. Indian Dermatol Online J 2022;13(3):375. [DOI:10.4103/idoj.idoj_364_21] [PMID]
  17. Patel M, Talwar D, Kumar S, Acharya S, Dubey A, Hulkoti V, Dronamraju S. Cutaneous mucormycosis with maxillary sinus fistula as a presenting feature of COVID-19: A rare case report. Med Sci. 2021;25(113):1507-2.
  18. Farid HA, Hashim AR, Hasrat NH. Rhinocerebral mucormycosis as a COVID-19-related complication: a case report from Basra city, Southern Iraq. J Glob Sci Res. 2021;6(5):1369-74.
  19. Roushdy T, Hamid E. A case series of post COVID-19 mucormycosis—a neurological prospective. Egypt. J Neurol Psychiatry Neurosurg. 2021;57:1-8. [DOI:10.1186/s41983-021-00355-8] [PMID]
  20. Saad RH, Mobarak FA. The diversity and outcome of post-covid mucormycosis: A case report. Int J Surg Case Rep. 2021;88:106522. [DOI:10.1016/j.ijscr.2021.106522] [PMID]
  21. Hamed H, Madia R, Ladadweh H, Falana H, AbuKhalil AD. Fatal mucormycosis post COVID-19 infection in uncontrolled diabetes with misuse of glucocorticoids and antibiotics. Infect Drug Resis. 2022; 1:1121-6. [DOI:10.2147/IDR.S356465] [PMID]
  22. Nehara HR, Puri I, Singhal V, Sunil IH, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol. 2021;39(3):380-3. [DOI:10.1016/j.ijmmb.2021.05.009] [PMID]
  23. Chauhan K, Soni D, Sarkar D, Karuna T, Sharma B, Singh S, Karkhur S. Mucormycosis after COVID-19 in a patient with diabetes. Lancet. 2021;398(10301):e10. [DOI:10.1016/S0140-6736(21)01641-X] [PMID]
  24. Mahler B, Parliteanu OA, Alexe O, Rîșcă Popazu C, Ene CE, Timar B, Constantinescu T. Mucormycosis in a Patient with Severe COVID-19 Disease—The First Case Report in Romania and a Literature Review. Medicina. 2023;59(3):555. [DOI:10.3390/medicina59030555] [PMID]
  25. Riad A, Shabaan AA, Issa J, Ibrahim S, Amer H, Mansy Y, Kassem I, Kassem AB, Howaldt HP, Klugar M, Attia S. COVID-19-associated mucormycosis (CAM): case-series and global analysis of mortality risk factors. J Fungus. 2021;7(10):837. [DOI:10.3390/jof7100837] [PMID]
  26. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, Mirhendi H, Salehi M, Tabari A, Mohammadi Ardehali M, Kord M. The double‐edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza‐associated mucormycosis versus COVID‐19 associated mucormycosis. Mycoses. 2021;64(8):798-808. [DOI:10.1111/myc.13256] [PMID]
  27. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, Barac A, Abdollahi A. Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses. 2021;64(10):1238-52. [DOI:10.1111/myc.13334] [PMID]
  28. Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E, Petrikkos G. Global cutaneous mucormycosis: a systematic review. J Fungus. 2022;8(2):194. [DOI:10.3390/jof8020194] [PMID]
  29. Nagalli S, Kikkeri NS. Mucormycosis in COVID-19: A systematic review of literature. Infez Med. 2021;29(4):504. [DOI:10.53854/liim-2904-2]
  30. Malhotra HS, Gupta P, Mehrotra D, Dandu H, Kohli N, Verma V, Kaur A, Kumar N, Prabhu V, Singh MK, Jaiswal R. COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee). J Oral Biol Craniofac Res. 2021;11(4):569-80. [DOI:10.1016/j.jobcr.2021.08.001] [PMID]
  31. Wang Y, Zhu M, Bao Y, Li L, Zhu L, Li F, Xu J, Liang J. Cutaneous mucormycosis caused by Rhizopus microsporus in an immunocompetent patient: a case report and review of literature. Medicine. 2018;97(25). [DOI:10.1097/MD.0000000000011141] [PMID]
  32. Liang GZ, Xu WQ, Zheng XL, Mei H, Lv GX, Shen YN, Li DM, Liu WD. Successful treatment by surgery of a primary cutaneous mucormycosis caused by mucor irregularis. Mycopathologia. 2018;183:445-9. [DOI:10.1007/s11046-017-0219-4] [PMID]